Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCLZiju Y. Xu-Monette, Ken H. Young, Min Xiao et al.|Cancer Immunology Research|2019Cited by 181
AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell LymphomaJinfen Wang, Ken H. Young, Zijun Y. Xu‐Monette et al.|American Journal Of Pathology|2017Cited by 60
XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53Manman Deng, Ken H. Young, Maurilio Ponzoni et al.|Journal of Hematology & Oncology|2020Cited by 56
Prognostic impact of c-Rel nuclear expression and<i>REL</i>amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphomaLing Li, Ken H. Young, Zijun Y. Xu‐Monette et al.|Oncotarget|2015Cited by 41
RelA NF-κB subunit activation as a therapeutic target in diffuse large B-cell lymphomaMingzhi Zhang, Ken H. Young, Zijun Y. Xu‐Monette et al.|Aging|2016Cited by 39